Zobrazeno 1 - 10
of 159
pro vyhledávání: '"Satoshi, Igawa"'
Autor:
Ou Yamaguchi, Keita Mori, Saori Takata, Kazuhiko Shibata, Kenichi Chikamori, Nozomu Kimura, Yoshiaki Nagai, Taku Nakagawa, Satoshi Igawa, Taishi Harada, Hiroshige Yoshioka, Hisashi Tanaka, Hitomi Nogawa, Hiroaki Satoh, Toshihiro Shiozawa, Kosuke Tsuji, Kunihiko Kobayashi, Kyoichi Kaira
Publikováno v:
Thoracic Cancer, Vol 15, Iss 2, Pp 163-171 (2024)
Abstract Background The factors that predict the clinical response to ramucirumab plus docetaxel (RD) after first‐line chemoimmunotherapy are unresolved. We explored whether the therapeutic efficacy of prior chemoimmunotherapy could predict the out
Externí odkaz:
https://doaj.org/article/69b23a7a31d74e76959dd39356a3e58f
Autor:
Tomoya Fukui, Jiichiro Sasaki, Satoshi Igawa, Akiko Kada, Toshiki I. Saito, Yoshihito Kogure, Hiroaki Okamoto, Katsuhiko Naoki
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-6 (2022)
Abstract Background Cancer chemotherapy indications for patients with poor performance status and advanced lung cancer are limited. Molecular targeted drugs, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors, can be used in
Externí odkaz:
https://doaj.org/article/b7905b38973a4120b686981c1e1fb89f
Autor:
Seiichiro Kusuhara, Satoshi Igawa, Masaaki Ichinoe, Ryo Nagashio, Yuki Kuchitsu, Yasuhiro Hiyoshi, Kazu Shiomi, Yoshiki Murakumo, Makoto Saegusa, Yukitoshi Satoh, Yuichi Sato, Katsuhiko Naoki
Publikováno v:
Thoracic Cancer, Vol 12, Iss 10, Pp 1570-1578 (2021)
Abstract Background Galectin‐3 (GAL3), a protein encoded by the LGALS3 gene, plays diverse roles in cancer initiation, progression, and drug resistance. Accordingly, high GAL3 expression in tumor cells is associated with poor prognosis in non‐sma
Externí odkaz:
https://doaj.org/article/4cda37681aad4fd8bc72fddb2db289c0
Autor:
Tomoya Fukui, Shinji Hosotani, Itaru Soda, Takahiro Ozawa, Seiichiro Kusuhara, Mikiko I. Kakegawa, Masashi Kasajima, Yasuhiro Hiyoshi, Satoshi Igawa, Masanori Yokoba, Hisashi Mitsufuji, Masaru Kubota, Masato Katagiri, Jiichiro Sasaki, Hiromichi Ishiyama, Katsuhiko Naoki
Publikováno v:
Thoracic Cancer, Vol 11, Iss 4, Pp 1005-1014 (2020)
Background The standard treatment for patients with unresectable locally advanced (LA) non‐small cell lung cancer (NSCLC) is chemoradiotherapy (CRT). Consolidation therapy with durvalumab after CRT demonstrated survival benefits and was approved in
Externí odkaz:
https://doaj.org/article/37b3391eaeba432cb841bcab53ea338a
Autor:
Yasuhiro Hiyoshi, Yuichi Sato, Masaaki Ichinoe, Ryo Nagashio, Daisuke Hagiuda, Makoto Kobayashi, Seiichiro Kusuhara, Satoshi Igawa, Kazu Shiomi, Naoki Goshima, Yoshiki Murakumo, Makoto Saegusa, Yukitoshi Satoh, Noriyuki Masuda, Katsuhiko Naoki
Publikováno v:
Thoracic Cancer, Vol 10, Iss 11, Pp 2142-2151 (2019)
Abstract Background Mitochondrial dysfunction contributes to many types of human disorders and cancer progression. Inner membrane mitochondrial protein (IMMT) plays an important role in the maintenance of mitochondrial structure and function. The aim
Externí odkaz:
https://doaj.org/article/9c18bcfeb1d04a0e906c19c6cd796b90
Autor:
Taihei Ono, Satoshi Igawa, Takahiro Ozawa, Masashi Kasajima, Mikiko Ishihara, Yasuhiro Hiyoshi, Seiichiro Kusuhara, Noriko Nishinarita, Tomoya Fukui, Masaru Kubota, Jiichiro Sasaki, Mitsufuji Hisashi, Masato Katagiri, Katsuhiko Naoki
Publikováno v:
Thoracic Cancer, Vol 10, Iss 4, Pp 880-889 (2019)
Background Osimertinib is recommended for non‐small cell lung cancer (NSCLC) patients with EGFR mutation; however, it is unclear whether body size variables affect the efficacy of osimertinib in such patients. This study assessed the potential effe
Externí odkaz:
https://doaj.org/article/762b2755eaa24337811d3fbfc457d213
Autor:
Tomoya Fukui, Mikiko Ishihara, Masashi Kasajima, Yasuhiro Hiyoshi, Yoshiro Nakahara, Sakiko Otani, Satoshi Igawa, Masanori Yokoba, Hisashi Mitsufuji, Masaru Kubota, Masato Katagiri, Jiichiro Sasaki, Katsuhiko Naoki
Publikováno v:
Thoracic Cancer, Vol 10, Iss 3, Pp 501-507 (2019)
Background Treatment strategies for patients with non‐small cell lung cancer (NSCLC) depend on various factors including physical condition, complications, tumor histology, and molecular profiling. Even if initial chemotherapy is efficacious, almos
Externí odkaz:
https://doaj.org/article/a8b1f88ecc404e40998e7769bdd2cfe6
Autor:
Masayuki Shirasawa, Tomoya Fukui, Seiichiro Kusuhara, Yasuhiro Hiyoshi, Yoshiro Nakahara, Noriko Nishinarita, Satoshi Igawa, Katsuhiko Naoki
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background Small cell lung cancer (SCLC) is characterized by a high propensity for metastases and a poor prognosis irrespective of high sensitivity for initial chemotherapy. Although interstitial pneumonia (IP) is one of risk factors for lun
Externí odkaz:
https://doaj.org/article/1783a8036d7b4874b38ed9119406a6d5
Autor:
Hiroya Manaka, Satoshi Igawa, Michiko Yamamoto, Akito Oguri, Hideaki Manabe, Masashi Kasajima, Seiichiro Kusuhara, Shinji Hosotani, Yoshiro Nakahara, Takashi Sato, Tomoya Fukui, Mitsufuji Hisashi, Jiichiro Sasaki, Katsuhiko Naoki
Publikováno v:
Investigational New Drugs. 41:115-121
Background: Thymic carcinoma is a very rare neoplasm for which no optimal chemotherapeutic regimen has been established to date. Hence, we performed this study to investigate the efficacy and safety of carboplatin plus nanoparticle albumin-bound (nab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42bbb6709e3f02604e97fa5890249b97
https://doi.org/10.1007/s10637-023-01327-w
https://doi.org/10.1007/s10637-023-01327-w
Autor:
Satoshi Ikeda, Terufumi Kato, Takashi Ogura, Akimasa Sekine, Tsuneyuki Oda, Noriyuki Masuda, Satoshi Igawa, Ken Katono, Sakiko Otani, Kouzo Yamada, Haruhiro Saito, Tetsuro Kondo, Yukio Hosomi, Yoshiro Nakahara, Masanori Nishikawa, Keiko Utumi, Yuki Misumi, Takeharu Yamanaka, Kentaro Sakamaki, Hiroaki Okamoto
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018)
Abstract Background Preclinical studies have demonstrated that docetaxel and bevacizumab may act synergistically by decreasing endothelial cell proliferation and preventing circulating endothelial progenitor mobilization. The objective of this study
Externí odkaz:
https://doaj.org/article/3fe632a26e484ce0a43859f5031a21b3